PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin.
Diana Canals HernaezMichael R HughesPamela DeanPeter BergqvistIsmael SamudioOla BlixtKatharina WiedemeyerYicong LiChris BondEric CruzMartin KöbelBlake GilksCalvin D RoskelleyKelly M McNagnyPublished in: Journal for immunotherapy of cancer (2021)
We have generated a novel and exquisitely tumor-restricted mAb, PODO447, that recognizes a glycoepitope on Podxl expressed at high levels by a variety of tumors including the majority of life-threatening high-grade serous ovarian tumors. Thus, tumor-restricted PODO447 exhibits the appropriate specificity for further development as a targeted immunotherapy.